Journal of Oncology / 2019 / Article / Tab 1

Review Article

The Role of Nonerythroid Spectrin II in Cancer

Table 1

SPTAN1 in various cancer types.

Tumor TypeChanges in SPTAN1References

Colorectal cancer (CRC)SPTAN1 upregulation[28]
SPTAN1 downregulation in MLH1-deficient CRC[29]
SPTAN1 upregulation in sporadic CRC, SPTAN1 downregulation in MLH1-deficient CRC[30]

Gastric cancerSPTAN1 upregulation[28, 31, 32]

Lung cancerSPTAN1 upregulation[33]
SPTAN1 mutations and downregulation[34]

Breast cancerSPTAN1 upregulation (cytoplasmic)[28, 35, 36]

Bladder cancerRecurrence-associated SPTAN1 alterations[37]

Prostate cancerSPTAN1 downregulation in lung metastasis, SPTAN1 as progression gene[38]

Cutaneous tumorsSPTAN1 upregulation (cytoplasmic)[39]

Soft-tissue tumorsSPTAN1 upregulation in more aggressive mesenchymal tumors[40]

Ovarian cancerSPTAN1 upregulation after chemotherapy[41]

Atypical chronic myeloid leukaemia (aCML)Novel CSF3R-SPTAN1 fusion gene[42]

Non-Hodgkin lymphomaSPTAN1 as target protein in postchemotherapy[43]

Non-Hodgkin lymphoma, acute lymphoblastic leukaemia (ALL)SPTAN1 upregulation after chemotherapy in nuclear area[44]

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.